Long-term side effects of glucocorticoids

Expert Opinion on Drug Safety

Volumn 15, Issue 4, 2016, Pages 457-465

  Oray, Merih ^a,b,c   Abu Samra, Khawla ^a,b   Ebrahimiadib, Nazanin ^a,b   Meese, Halea ^a,b   Foster, C Stephen ^a,b,d  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Ocular Immunology and Uveitis Foundation   (United States)

^c ISTANBUL UNIVERSITY   (Turkey)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

corticosteroids; glucocorticoids; immunosuppression; side effects

Indexed keywords

BETAMETHASONE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID; GLUCOSE; LIVE VACCINE; MINERALOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; STEROID; TRIAMCINOLONE; VITAMIN D;

ADRENAL SUPPRESSION; ADVERSE DRUG REACTION; AVASCULAR NECROSIS; BONE DENSITY; BONE NECROSIS; CATARACT; CELLULAR IMMUNITY; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GLUCOSE METABOLISM; GROWTH INHIBITION; GROWTH RETARDATION; HEART DISEASE; HUMAN; HYPERTENSION; IMMUNOPATHOLOGY; INFECTION; LONG TERM CARE; MENTAL DISEASE; MYOPATHY; OSTEOPOROSIS; PHYSICIAN; PREVENTIVE MEDICINE; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SECONDARY OSTEOPOROSIS; SIDE EFFECT; SKIN DISEASE; WEIGHT GAIN; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; RISK;

DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLUCOCORTICOIDS; HUMANS; RISK;

EID: 84958068868     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2016.1140743     Document Type: Review

References (62)

1. Hench PS, Kendall EC, Slocumb CH, et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc. 1949;24:181-197.
2. Hench PS, Kendall EC, Slocumb CH, et al. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever, and certain other conditions. Arch Intern Med (Chic). 1950;85:545-666.
3. Ericson-Neilsen W, Kaye AD. Steroids: pharmacology, complications, and practice delivery issues. Ochsner J. 2014;14:203-207.
4. Van der Goes M, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases-positive and adverse effects. Arthritis Res Ther. 2014;16 Suppl 2:S2.
5. Curtis JR, Westfall AO, Allison J, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55:420-426.
6. Pereira RM, Carvalho JF, Canalis E. Glucocorticoidinduced osteoporosis in rheumatic diseases. Clinics (Sao Paulo). 2010;65:1197-1205.
7. van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15:993-1000.
8. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County rheumatoid arthritis register. Arthritis Rheum. 2000;43:522-530.
9. De Nijs RN. Glucocorticoid-induced osteoporosis: A review on pathophysiology and treatment options. Minerva Med. 2008;99:23-43.
10. Daens S, Peretz A, de Maertelaer V, et al. Efficiency of quantitative ultrasound measurements as compared with dual-energy x-ray absorptiometry in the assessment of corticosteroid-induced bone impairment. Osteoporos Int. 1999;10:278-283.
11. Hooyman JR, Melton LJ, Nelson AM, et al. Fractures after rheumatoid arthritis-A population based study. Arthritis Rheum. 1984;27:1353-1361.
12. Baranova IA, Ershova OB, Anaev EK. Analysis of the stateof-The-art of consulting medical care to patients with glucocorticoid-induced osteoporosis or its risk according to the data of a questionnaire survey (GLUCOST study). Ter Arkh. 2015;87:58-64.
13. Gourlay M, Franceschini N, Sheyn Y. Prevention and treatment strategies for glucocorticoid-induced osteoporotic fractures. Clin Rheumatol. 2007;26:144-153.
14. Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41:595-611.
15. Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41:183-190.
16. Cushing H. The basophil adenoma of the pituitary body and their clinical manifestation. Johns Hopkins Med. 1932;50:137.
17. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoid-induced myopathy. J Endocrinol. 2008;197:1-10.
18. Olefsky JM, Kimmerling G. Effects of glucocorticoids on carbohydrate metabolism. Am J Med Sci. 1976;271:202-210.
19. McMahon M, Gerich J, Rizza R. Effects of glucocorticoids on carbohydrate metabolism. Diabetes Metab Rev. 1988;4:17-30.
20. Arnaldi G, Scandali VM, Trementino L, et al. Pathophysiology of dyslipidemia in Cushing's syndrome. Neuroendocrinology. 2010;92(Suppl 1):86-90.
21. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: The Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2005;53:528-535.
22. Da Silva JA, Jacobs JW, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285-293.
23. Braith RW, Welsch MA, Mills RM Jr, et al. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc. 1988;30:483-489.
24. Aceto T, Beckhorn GD, Jorgensen JR, et al. Iatrogenic ACTH-cortisol insufficiency. Pediatr Clin North Am. 1966;13:543-557.
25. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114:735-740.
26. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med. 1991;115:787-796.
27. Hill RB Jr. Fatal fat embolism from steroid-induced fatty liver. N Engl J Med. 1961;265:318-320.
28. Sadr-Azodi O, Mattsson F, Bexlius TS, et al. Association of oral glucocorticoid use with an increased risk of acute pancreatitis: A population-based nested case-control study. JAMA Intern Med. 2013;173:444-449.
29. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619-632.
30. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68:1119-1124.
31. Sato A, Funder JW, Okubo M, et al. Glucocorticoidinduced hypertension in the elderly. Relation to serum calcium and family history of essential hypertension. Am J Hypertens. 1995;8:823-828.
32. Fardet L, Feve B. Systemic glucocorticoid therapy: A review of its metabolic and cardiovascular adverse events. Drugs. 2014;74:1731-1745.
33. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764-770.
34. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170-1175.
35. Van der Hooft CS, Heeringa J, Brusselle GG, et al. Corticosteroids and the risk of atrial fibrillation. Arch Intern Med. 2006;166:1016-1020.
36. Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90:859-865.
37. Werth VP. Management and treatment with systemic glucocorticoids. Adv Dermatol. 1993;8:81-103.
38. Kaya G. New therapeutic targets in dermatoporosis. J Nutr Health Aging. 2012;16:285-288.
39. Kaya G, Saurat JH. Dermatoporosis: A chronic cutaneous insufficiency/fragility syndrome. Clinicopathological features, mechanisms, prevention and potential treatments. Dermatology. 2007;215:284-294.
40. Brown ES, Chandler PA. Mood and cognitive changes during systemic corticosteroid therapy. Prim Care Companion J Clin Psychiatry. 2001;3:17-21.
41. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroidinduced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol. 2007;157:142-148.
42. Brown ES, Rush AJ, McEwen BS. Hippocampal remodeling and damage by corticosteroids: implications for mood disorders. Neuropsychopharmacology. 1999;21:474-484.
43. Barrimi M, Aalouane R, Aarab C, et al. [Prolonged corticosteroid-therapy and anxiety-depressive disorders, longitudinal study over 12 months]. Encephale. 2013;39:59-65.
44. Boston Collaborative Drug Study. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther. 1972;13:694-698.
45. Lewis DA, Smith RE. Steroid-induced psychiatric syndromes: A report of 14 cases and a review of the literature. J Affect Disord. 1983;5:319-332.
46. Fel A, Aslangul E, Le Jeunne C. [Eye and corticosteroid's use]. Presse Med. 2012;41:414-421.
47. James ER. The etiology of steroid cataract. J Ocul Pharmacol Ther. 2007;23:403-420.
48. Tripathi RC, Parapuram SK, Tripathi BJ, et al. Corticosteroids and glaucoma risk. Drugs Aging. 1999;15:439-450.
49. Miller D, Peczon JD, Whitworth CG. Corticosteroids and functions in the anterior segment of the eye. Am J Ophthalmol. 1965;59:31-34.
50. Haimovici R, Koh S, Gagnon DR, et al. Central Serous Chorioretinopathy Case-Control Study Group. Risk factors for central serous chorioretinopathy: A case-control study. Ophthalmology. 2004;111:244-249.
51. Dale DC, Petersdorf RG. Corticosteroids and infectious diseases. Med Clin North Am. 1973;57:1277-1287.
52. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11:954-963.
53. Grossi O, Genereau T. [Glucocorticoids and infections, doping, surgery, sexuality]. Rev Med Interne. 2013;34:269-278.
54. van der Goes MC, Jacobs JW, Boers M, et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. 2010;69:1913-1919.
55. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359-2381.
56. U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the surgeon general. Rockville (MD): U.S. Department of Health and Human Services, Office of the Surgeon General; 2004.
57. American College of Rheumatology. Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis: 2001 update. Arthritis Rheum. 2001;44:1496-1503.
58. Hoes JN, Jacobs JW, Boers M, et al. EULAR evidencebased recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560-1567.
59. Schacke H, Berger M, Rehwinkel H, et al. Selective glucocorticoid receptor agonists (SE GRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275:109-117.
60. Reuter KC, Grunwitz CR, Kaminski BM, et al. Selective glucocorticoid receptor agonists for the treatment of inflammatory bowel disease: studies in mice with acute trinitrobenzene sulfonic acid colitis. J Pharmacol Exp Ther. 2012;341:68-80.
61. Quan L, Zhang Y, Crielaard BJ, et al. Nanomedicines for inflammatory arthritis: head-to-head comparison of glucocorticoid-containing polymers, micelles, and liposomes. ACS Nano. 2014;8:458-466.
62. Elbialy NS, Abdol-Azim BM, Shafaa MW, et al. Enhancement of the ocular therapeutic effect of prednisolone acetate by liposomal entrapment. J Biomed Nanotechnol. 2013;9:2105-2116.